Cervical dilatation with sulprostone prior to vacuum aspiration. A two-dose, randomized study

Area of Science:

• Obstetrics and Gynecology
• Pharmacology

Background:

• First-trimester abortions often involve surgical procedures like vacuum aspiration.
• Cervical preparation prior to surgical abortion can improve outcomes.
• Sulprostone (16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulfonylamide) is a prostaglandin E2 analogue.

Purpose of the Study:

• To compare the efficacy and tolerance of two doses of Sulprostone as a pretreatment for vacuum aspiration.
• To evaluate the impact of Sulprostone dosage on cervical dilation, blood loss, and side effects.

Main Methods:

• A randomized study involving 200 patients undergoing first-trimester pregnancy termination.
• Patients received either 250 or 500 micrograms of Sulprostone intramuscularly three hours before vacuum aspiration.
• Data collected included cervical dilatation, blood loss, operative complications, side effects, and analgesic use.

Main Results:

• Both 250 and 500 microgram doses of Sulprostone were equally effective in cervical dilation and controlling blood loss.
• Increasing the Sulprostone dose to 500 micrograms did not result in significantly greater cervical dilation.
• The 500 microgram dose was associated with a higher incidence of gastro-intestinal side effects and increased need for analgesia.

Conclusions:

• Sulprostone is effective for cervical preparation prior to vacuum aspiration in early pregnancy termination.
• The 250 microgram dose of Sulprostone appears to offer a favorable balance between efficacy and tolerance.
• Higher doses of Sulprostone do not enhance cervical dilation but increase adverse events and patient discomfort.